Lantheus acquires radiopharma CDMO Evergreen
The US radiopharmaceuticals giant Lantheus is snapping up the Contract Development and Manufacturing (CDMO) Evergreen Theragnostics as it expands its radiopharmaceuticals business. The deal, which...
Ethris reports positive phase 1 results for ETH47 mRNA asthma treatment
Munich-based biotechnology company Ethris has announced encouraging topline data from a phase 1 clinical trial evaluating its lead messenger RNA (mRNA) candidate, ETH47. The therapy...
Novo Nordisk reports 22% weight loss with amycretin
Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug,...
Manas AI launches with $24.6 million seed round
The round was led by the US venture capital (VC) firm General Catalyst Partners with participation from compatriot VC Greylock Partners in addition to strategic...
Applying data to real-world challenges
Head of solution value at One2Treat, Émilie Barré shares her journey to date with Outsourcing-Pharma. Could you give us an overview of your work? I...
The largest pharma acquisitions of 2024
Compared to the previous years, 2024 has been a relatively slow year for mergers and acquisitions in the pharmaceutical space. The largest acquisition of 2024...
Arctic therapeutics secures funding for groundbreaking dementia and acne treatments
Arctic Therapeutics announced this week that it has raised €26.5 million, a sum bankrolled by investors including the European Innovation Council (EIC) Fund, the Icelandic...
AI proving critical in clinical trial design
We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025 Achievements and milestones...
Trial shows high-dose Wegovy can increase weight loss effects
Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for....
BioCina and NovaCina join forces in merger
Australian contract development and manufacturing organizations (CDMOs), BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise and...
Spotlight on patient centricity in clinical trials
We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient centricity in terms of clinical...
Medable Showcases AI-Powered Innovations at SCOPE 2025
Stakeholders across the clinical trials and digital health industry will be gathering next month in Orlando at the Summit for Clinical OPS Executives (SCOPE) 2025....
Tech key to accelerating clinical trial outcomes
Ashley Davidson, vice president of sponsor and tech strategy at Advarra, discusses her outlook for this year’s edition of the SCOPE summit. The global market...
WCG’s outlook for SCOPE 2025
As pharmaceutical pipelines and R&D investments expand worldwide, the global market for clinical trials is projected to grow by almost 9% per year from $48.2...
Patient Perspectives and Multidimensional Assessments
The evolution of clinical trials is being driven by an increased focus on patient perspectives and innovative statistical methodologies. Regulatory agencies are pushing for trials...
Johnson & Johnson acquires Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has entered an acquisition agreement with drug developer Intra-Cellular Therapies priced at $14.6bn, positioning the deal as one of the largest seen...
Scope Summit 2025 award finalists announced
As the Cambridge Healthtech Institute (CHI) celebrates its 16th annual Clinical Ops Executives (SCOPE) Summit in Orlando, Florida, USA, next month, two awards, one for...
Anthem Biosciences plans IPO worth $397m
As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences is planning to raise 33.95 billion rupees...
Verdiva Bio’s launch is backed by financing of over $410m
The company’s launch is backed by an oversubscribed Series A round of $411m co-led by Forbion and General Atlantic. RA Capital Management, OrbiMed, Logos Capital,...
Denali’s ALS Drug DNL343 Misses Key Trial Endpoint
Denali Therapeutics has announced topline results from the phase 2/3 Healey ALS Platform Trial, which evaluated the effects of its drug candidate DNL343. The study...
Orbis Medicines bags €90 million Series A
Orbis was founded in 2021 by the Seeds Investment team of Novo Holdings, the assets and wealth manager of the Novo Nordisk Foundation. The company...
Bremelanotide: Promising Diabetic Nephropathy Treatment
Palatin Technologies has announced topline results for the phase 2b Breakout study, which evaluated the effects of bremelanotide in patients with type 2 diabetic nephropathy....
Gilead taps into Terray’s AI-based drug discovery
According to the terms of the deal, Gilead will select a set of drug targets and Terray will discover and develop small molecule drugs that...
Brazil’s Nintx bags $10m for plant-based drugs
Founded by a team of scientists and healthcare specialists in 2021, Nintx harnesses compounds from Brazil’s world-famous plant ecosystems to develop treatments for complex, multifactorial...
AbbVie acquires Nimble for oral peptides
AbbVie and Nimble Therapeutics have announced an acquisition deal in which AbbVie will gain ownership of the company’s pipeline of oral peptide candidates. As part...
General Inception acquires Enable Medicine
The company creator General Inception (GI) has acquired Enable Medicine to pool its know-how regarding drug development and the biotech ecosystem with the latter’s biological...
Noema Pharma Secures $147M to Advance CNS Disorder Treatments
Noema Pharma has announced an extension of its series B financing round, bringing the total raised up to $147 million (CHF 130 million). The round...
Eli Lilly expansion set to add 750 skilled jobs to Wisconsin site
Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity...
AbbVie set to file for FDA approval on tavapadon
Pharma company, AbbVie, reports that its D1/D5 partial agonist, tavapadon, has met the primary and secondary endpoints in a pivotal Phase 3 trial. The trial,...
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
PTC Therapeutics announced this week that it has made a deal with Novartis for global rights to its oral Huntington’s disease candidate PTC518, a splicing...
Investment in radiopharmaceuticals is ramping up
Investment in radiopharmaceuticals is ramping up as big pharma shows a growing appetite for this promising drug modality. Radiopharmaceuticals see radioactive isotopes being delivered into...
Mitsubishi and Dewpoint team up to tackle ALS
The pharma arm of Mitsubishi Chemical Group has launched a collaboration with US-based Dewpoint Therapeutics to co-develop a preclinical-stage treatment for the neurological condition amyotrophic...
Körber absorbs Bähren to expand pharma packaging
The pharmaceutical business unit of the German giant Körber has snapped up the compatriot label and leaflet supplier Wilhelm Bähren GmbH & Co as the...
Novocure’s TTFields therapy boosts survival in pancreatic cancer
Swiss oncology specialist Novocure has announced positive topline results from the PANOVA-3 phase 3 clinical trial, which evaluated the use of tumor treating fields (TTFields)...
Tech-driven solutions for patient access
While these sites are important for clinical research, they make patient recruitment challenging. Many participants are forced to travel to these locations for recurring visits,...
Overcoming nonspecific binding challenges in PK assays
However, nonspecific binding (NSB) can hinder PK assays, impacting their accuracy and reliability. Fortunately, there are strategies and best practices to counter this issue. NSB...
Diabetes prevention – Eli Lilly’s Tirzepatide shows 23% weight loss
Eli Lilly has released detailed results from the SURMOUNT-1 phase 3 trial, where over 1,000 obese or overweight prediabetic participants were followed over the course...
Equity boost and partnership aim to accelerate GEMS platform’s efficiency
NVentures also participated in the company’s $200 million Series B last August. This strengthened collaboration is aimed at advancing Genesis’ capabilities to tackle complex and...
AstraZeneca invests $3.5BN to boost US manufacturing power
With around $2 billion of the investment dedicated to creating more than a thousand U.S. jobs, AstraZeneca is looking to expand R&D and manufacturing facilities...
FDA grants orphan drug designation to CervoMed’s dementia drug
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational small molecule drug, Neflamapimod, for the treatment...
Portugal’s Hovione builds spray drying capacity in US and Ireland
Spray drying involves converting pharmaceutical liquid solutions into tiny droplets that are rapidly dried with hot gases such as nitrogen. This turns medicinal products into...
Phase 3 success for AstraZeneca prostate drug
AstraZeneca has reported positive results from the CAPItello-281 phase 3 trial, which evaluated Truqap (capivasertib) in combination with Johnson & Johnson’s Zytiga (abiraterone) and androgen...
We’ve upgraded Outsourcing Pharma to give you more of what you love
What’s new at leading trade publication Outsourcing Pharma...
Adragos Pharma snaps up Baccinex to expand CDMO network
Founded in Munich in 2020, Adragos’ global manufacturing sites were acquired from other players including Haupt Pharma Livron, LAW Pharma, Sanofi and Fresenius Kabi. They...
Decentralized clinical trials market expected to grow to $25BN
According to a recent report by Business Research Insights, the total size of the global decentralized clinical trials market was $7.14 billion in 2023, a...
How eCOA/ePRO is transforming clinical trials
eCOA and ePRO (electronic patient-reported outcome) technology are transforming clinical trials, offering streamlined processes for patients, sites, and sponsors. In this Q&A, Steve shares how...
C Ray Therapeutics $100M to improve RDC technology platform
C Ray Therapeutics has announced the completion of a series A+ financing round, which has exceeded the $100 million mark. The round was co-led by...
Promising phase 2 results for Eli Lilly’s Muvalaplin
Yesterday, Eli Lilly and Company revealed promising Phase 2 results for its investigational small molecule drug, Muvalaplin, against cardiovascular events. The drug met its primary...
Chemistry passion to industry leadership
Now the Global market development manager at Phenomenex, she thrives on connecting insights with solutions, all while channeling the wisdom of her science-loving microbiologist father....
From lab to leading biopharma innovation
Now leading the Biopharma product management team at Phenomenex, she brings a problem-solving mindset honed by a love of forensic science and analytical chemistry. Her...
Samsung Biologics and European pharma company enter major manufacturing deal
The global contract development and manufacturing organization (CDMO), Samsung Biologics, announced this week that it has entered into a collaboration with an undisclosed European pharmaceutical...
Pfizer’s HYMPAVZI wins EU approval for hemophilia A and B care
The US big pharma company Pfizer has been granted marketing authorization for its hemophilia A and B treatment, HYMPAVZI (marstacimab), by the European Commission based...
Drug-free pain relief for knee osteoarthritis
Sameer Sabir, CEO and co-founder of Brixton Biosciences, aims to revolutionize pain management. With Neural Ice, the company’s groundbreaking drug-free therapy, Brixton aims to offer...
Icotrokinra ‘best in class oral therapeutic for plaque psoriasis’
The phase 3 ICONIC-LEAD study showed that icotrokinra, a peptide drug that blocks the interleukin (IL)-23 receptor, was able to induce significant clearance of psoriatic...
Pfizer’s HYMPAVZI wins EU approval for hemophilia A and B care
The US big pharma company Pfizer has been granted marketing authorization for its hemophilia A and B treatment, HYMPAVZI (marstacimab), by the European Commission based...
C Ray Therapeutics $100M to improve RDC technology platform
C Ray Therapeutics has announced the completion of a series A+ financing round, which has exceeded the $100 million mark. The round was co-led by...
Promising phase 2 results for Eli Lilly’s Muvalaplin
Yesterday, Eli Lilly and Company revealed promising Phase 2 results for its investigational small molecule drug, Muvalaplin, against cardiovascular events. The drug met its primary...
GHO and Ampersand acquire CDMO Avid Bioservices for $1.1 billion
Under the terms of the merger agreement, Avid Bioservices will be acquired by funds managed by GHO and Ampersand in a transaction valued at $1.1...
Coronado’s CSO champions data-driven innovation in clinical trials
At the helm of Coronado’s scientific strategy, Professor Visser-Rogers envisions a data-driven future powered by innovative methodologies and emerging technologies. Her approach emphasizes not only...
Gifthealth partners with United Digestive
Gifthealth has announced a strategic partnership with United Digestive, a leading practice management organization for gastroenterology. This is to enhance patient access and improve preparation...
Patients prefer telehealth for clinical trials, survey shows
Conducted with 136 US-based participants across multiple health conditions, the survey found that 63% said they would be more likely to join a trial if...
AI-driven Medable Studio speeds digital trial startups
Medable, a provider of clinical development technology, has announced a collaboration with Google Cloud to bring its decentralized clinical trial platform to Google Cloud Marketplace,...
Overcoming nonspecific binding challenges in PK assays
However, nonspecific binding (NSB) can hinder PK assays, impacting their accuracy and reliability. Fortunately, there are strategies and best practices to counter this issue. NSB...
Equity boost and partnership aim to accelerate GEMS platform’s efficiency
This forms part of an expanded partnership to enhance Genesis’ AI-powered drug discovery platform, GEMS (Genesis Exploration of Molecular Space). The new investment follows NVentures’...
Diabetes prevention – Eli Lilly’s Tirzepatide shows 23% weight loss
Eli Lilly has released detailed results from the SURMOUNT-1 phase 3 trial, where over 1,000 obese or overweight prediabetic participants were followed over the course...
AstraZeneca invests $3.5BN to boost US manufacturing power
With around $2 billion of the investment dedicated to creating more than a thousand U.S. jobs, AstraZeneca is looking to expand R&D and manufacturing facilities...
Tech-driven solutions for patient access
While these sites are important for clinical research, they make patient recruitment challenging. Many participants are forced to travel to these locations for recurring visits,...
Decentralized clinical trials market expected to grow to $25BN
According to a recent report by Business Research Insights, the total size of the global decentralized clinical trials market was $7.14 billion in 2023, a...
Merck, Abbisko’s oral drug aces phase 3 for rare tumors
According to the topline results, a total of 54% of patients given the treatment saw their tumors shrink compared to just 3.2% in the placebo...
Dexter Tjoa on Tjoapack’s journey and future in packaging
CEO Dexter Tjoa shares insights on the company’s journey, from early barcoding breakthroughs to embracing advanced technologies for patient safety, sustainability, and global compliance. Discover...
Axonis raises $115 million to treat epilepsy
Epilepsy is one of the most common neurological conditions in the world, with around 50 million people with the condition. There are a variety of...
Abzena unveils cell Line and ADC innovations at CPHI 2024
By offering comprehensive, integrated solutions, Abzena aims to streamline drug development processes and minimize risks for customers, helping to accelerate timelines and enhance production. OSP...
Middle School MD fosters youth interest in medical careers
The Palomar Health Foundation recently completed its third annual Middle School Medical Discoveries (Middle School MD) program, engaging local youth in immersive learning sessions aimed...
Novo Nordisk signs $285 million deal for a once-monthly Wegovy
Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to its TransCon technology platform for the development, manufacturing and commercialization of Novo’s products in...
Senhwa Biosciences starts trial of drug for rare cancers in children
Silmitasertib, also known as CX-4945, was originally developed by Cylene Pharmaceuticals, a San Diego-based biotech that ceased operations in 2013. Since then, Senhwa Biosciences, which...
Veeva’s Tim Davis on overcoming eCOA deployment challenges
Tim Davis, vice president of strategy at Veeva eCOA, had a conversation with Outsourcing Pharma’s senior editor, Liza Laws, and sheds light on how the...
MD Anderson investment supports groundbreaking cancer therapies
Starget Pharma, an Israeli startup developing AI-powered precision therapies for difficult-to-treat cancers, has secured a $5.1 million investment from MD Anderson Cancer Center’s Cancer Focus...
Novo Nordisk study – semaglutide reduces hospital admissions
Novo Nordisk has released data from the SELECT phase 3 trial showing that a 2.4 mg dose of semaglutide reduced the number of hospital admissions...
First-line leukemia therapy granted accelerated approval by FDA
Novartis’ Scemblix (asciminib) has received accelerated approval by the US FDA as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive myeloid leukemia in...
AI-driven outreach boosts therapy start, adherence rates
A new case study from AllazoHealth demonstrates that a top 10 rare disease pharmaceutical company experienced a 10.4% increase in therapy initiation through AI-driven patient...
Labguru ELN integration enhances Thermo Fisher LIMS capabilities
This integration aims to create a unified lab management experience, offering scientists enhanced data traceability, security, and streamlined workflows across a wide range of laboratory...
Vicky Marriott on leading with empathy in science and statistics
In an exclusive interview, Vicky shares insights on her career, the challenges she faced, and her passion for inspiring the next generation of women in...
Enhancing pharma manufacturing with digital twin technology
From reducing operational costs to enhancing patient outcomes, Stevanato Group is at the forefront of digital transformation in pharma. Digital Twin Technology: How has the...